Novo Nordisk (NVO) declined to comment on when the company would end production of human insulin pens, adding that the pens were different from those used for its hugely popular GLP-1 drugs ...

The pioneering Danish drugmaker was once the most valuable company in Europe, but analysts say a number of missteps reversed ...

Novo Nordisk said its price reductions would go into effect at the start of next year. The list price of a vial of rapid-acting NovoLog, one of the most widely used insulin products, will fall to ...

Novo Nordisk said Tuesday it will slash the list prices of several of its popular pre-filled insulin pens and vials by up to 75%, becoming the latest drugmaker to reduce the cost of the critical ...

According to MSF, a prefilled human insulin pen could be sold at a profit at an estimated generic target price of just $0.94. The estimate informed the call for Lilly, Novo, Sanofi and other ...

Patients with diabetes using a NovoPen Echo from one of the affected batches listed above should call Novo Nordisk at 1-855-419-8827 between 8 a.m. and 6 p.m. Eastern time to get a replacement ...

MSF estimates insulin pens can be produced for $0.94 while being profitable; current U.S. price is $90.69. Diabetes affects 537 million globally, with African cases expected to rise by 134% by ...

Both pens have 1-unit increments in dosing. NovoLog ® should not be mixed with any other insulin when used in a pump or with any insulin other than NPH when used with injections by syringe, the ...

Novo Nordisk is looking to double the production capacity of insulin doses and increase the volume of production of Flexpen, an insulin injection pen of the latest generation. Show Conversation (0) ...

Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other injected diabetes medications such as Ozempic. Read more.